Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
2.

Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.

Constantinescu R, Krýsl D, Andrén K, Asztély F, Bergquist F, Zetterberg H, Andreasson U, Axelsson M, Menachem EB, Jons D, Mahamud U, Malmeström C, Rosengren L, Blennow K.

J Neuroimmunol. 2017 May 15;306:25-30. doi: 10.1016/j.jneuroim.2017.02.018. Epub 2017 Mar 1.

PMID:
28385184
3.

Early hematopoiesis in multiple sclerosis patients.

Jons D, Kneider M, Fogelstrand L, Jeppsson A, Jacobsson S, Andersen O.

J Neuroimmunol. 2016 Oct 15;299:158-163. doi: 10.1016/j.jneuroim.2016.09.004. Epub 2016 Sep 13.

PMID:
27725115
4.

[Deficits related to the academic environment inhibit resident physicians to conduct research. A questionnaire among resident physicians in Gothenburg].

Gonzalez H, Bentley L, Holst A, Jons D, Wallén S, Kindblom J.

Lakartidningen. 2010 Sep 22-28;107(38):2248-50. Swedish. No abstract available.

PMID:
21043169

Supplemental Content

Loading ...
Support Center